Radiation plus immunotherapy shows promise for hard-to-treat stomach cancers
NCT ID NCT03610711
First seen Jan 08, 2026 · Last updated May 14, 2026 · Updated 19 times
Summary
This study tests whether adding targeted radiation to the immunotherapy drug nivolumab (alone or with another drug, relatlimab) can help control advanced stomach, esophageal, or gastroesophageal junction cancer. About 21 adults with limited metastatic disease will receive radiation to some tumors, then immunotherapy to see if it boosts the immune attack on cancer throughout the body. The main goal is safety and measuring immune cell changes, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alleghany Health Network
Pittsburgh, Pennsylvania, 15212, United States
-
Baylor University
Dallas, Texas, 75246, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.